Avacta Group Plc Share Price London S.E.
Equities
GB0033519546
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-01 | Avacta picks Christina Coughlin to replace long-serving CEO | AN |
Sales 2023 | 23.25M 29.11M 2.32B | Sales 2024 * | 24.5M 30.68M 2.45B | Capitalization | 162M 202M 16.16B |
---|---|---|---|---|---|
Net income 2023 | -24M -30.05M -2.4B | Net income 2024 * | -27M -33.81M -2.7B | EV / Sales 2023 | 14 x |
Net cash position 2023 * | 16.2M 20.28M 1.62B | Net cash position 2024 * | 22.4M 28.05M 2.24B | EV / Sales 2024 * | 5.68 x |
P/E ratio 2023 |
-12.7
x | P/E ratio 2024 * |
-5.88
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.66% |
Latest transcript on Avacta Group Plc
Managers | Title | Age | Since |
---|---|---|---|
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 03/01/16 |
Matt Johnson
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/13 |
Michael Vinegrad
IRO | Public Communications Contact | - | 31/05/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Trevor Nicholls
BRD | Director/Board Member | 67 | 01/08/13 |
Tony Gardiner
DFI | Director of Finance/CFO | 53 | 03/01/16 |
Paul Fry
BRD | Director/Board Member | 58 | 02/02/20 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |